We read with interest Uyar and colleagues' recent report on the association between diabetes, nondiabetic elevated glycated hemoglobin levels (HbA1c), and neuroaxonal damage in Parkinson's disease (PD) patients from the MARK‐PD study. 1 The authors confirmed previously established findings of an inverse association between diabetes and cognitive and motor status. The authors also demonstrated higher serum neurofilament light (NfL) levels (a marker of neuroaxonal damage) 2 in PD patients with prevalent type 2 diabetes and in PD patients with nondiabetic elevated HbA1c levels. These associations persisted after adjustment for age, body mass index (BMI), and vascular risk factors (prevalent arterial hypertension, hypercholesterolemia, and history of stroke). We recently noted similar motor and cognitive associations in PD patients with diabetes 3 in the Tracking Parkinson's study, although only a nonsignificant trend toward an association in the overall PD cohort between NfL levels and more severe motor and cognitive status at baseline,4 which may reflect the reduced disease duration in the Tracking Parkinson's cohort, compared with the MARK‐PD cohort.
Considering the authors' novel findings of an association between diabetes and neuroaxonal damage, we explored the relationship between serum NfL and diabetes in our previously defined subgroup of the Tracking Parkinson's study. 4 The analysis was performed using Stata V.17.0 (Stata, RRID:SCR_012763), and differences were compared using Kruskal–Wallis tests for continuous data and χ2 tests for categorical data, whereas the association between NfL and diabetes was further explored using univariate and multivariate (age, BMI, and vascular risk factors) linear regression analysis.
Of the 280 patients studied, 29 suffered from prevalent type 2 diabetes. PD‐DM patients were older (74.1 years ± SD 7.7 vs. 68.1 years ± 8.7, P < 0.001), with higher BMIs (31.1 ± SD [standard deviation] 5.7 vs. 27.1 ± SD 4.4, P < 0.001), whereas a higher proportion had coexistent vascular risk factors than PD patients without diabetes (P = 0.032). Serum NfL levels were higher in PD‐DM patients (39.5 ± SD 18.9 vs. 29.6 ± SD 16.0, P < 0.001). Using regression analysis, NfL levels were significantly associated with patients' diabetic status (coefficient: 0.82, 95% CI [confidence interval]: 0.45–1.19, P < 0.0001), which persisted (coefficient: 0.52, 95% CI: 0.18–0.86, P = 0.003) after adjustment for age, BMI, and vascular risk factors (history of angina, myocardial infarction, stroke, hypertension, and hypercholesterolemia).
Our findings affirm Uyar et al's report of an association between PD‐DM and more severe neuroaxonal damage. Furthermore, the data indicate that the more severe phenotype in PD‐DM noted to date by several studies is likely to be mediated by additional factors other than vascular risk factor burden that tends to coexist in these cases. T2DM and PD share several pathological processes encompassing neuroinflammation, lysosomal dysfunction, mitochondrial dysfunction, and the development of central insulin resistance that leads to neurodegeneration. 5 This process is in part mediated by hyperglycemia as demonstrated by the MARK‐PD study and its downstream impact on α‐synuclein aggregation. 6 It is also possible that some of the observed associations are explained by diabetic neuropathy, as other peripheral neuropathies are known to increase blood NfL concentrations. 7 Disentangling the mechanistic factors that contribute to this more rapidly progressive axonal damage is of critical importance in the development of disease‐modifying therapies for PD.
Full financial disclosures for the previous 12 months
N.V. has received unconditional educational grants from Ipsen and Biogen; travel grants from Ipsen, AbbVie, and the International Parkinson's Disease and Movement Disorders Society; and speaker's honorarium from AbbVie and Stada and served on advisory boards for AbbVie and Brittania outside of the submitted work.
M.L. has no competing interest.
R.R. has no competing interest.
A.J.H. has no competing interest.
T.G. has no competing interest.
D.A. has no competing interest.
C.G. has no competing interest.
Y.B.‐S. has no competing interest.
H.Z. has served at scientific advisory boards for AbbVie, Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, and CogRx; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen; and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside the submitted work).
D.G.G. has received honoraria from Bial Pharma, GE Healthcare, and Vectura plc and consultancy fees from the Glasgow Memory Clinic.
H.R.M. is employed by UCL. In the past 24 months he reports paid consultancy from Biogen, UCB, AbbVie, Denali, Biohaven, and Lundbeck; lecture fees/honoraria from Biogen, UCB, C4X Discovery, GE‐Healthcare, Wellcome Trust, and Movement Disorders Society; and research grants from ASAP, Parkinson's UK, Cure Parkinson's Trust, PSP Association, CBD Solutions, Drake Foundation, and Medical Research Council. Dr. Morris is a co‐applicant on a patent application related to C9ORF72—Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140).
T.F. has received grants from the National Institute of Health Research, The Michael J. Fox Foundation, John Black Charitable Foundation, Cure Parkinson's Trust, Innovate UK, Van Andel Research Institute, and Defeat MSA. He has served on advisory boards for Voyager Therapeutics, Handl Therapeutics, Living Cell Technologies, Bial, and Profile Pharma. He has received honoraria for talks sponsored by Bial, Profile Pharma, and Boston Scientific.
Author Roles
Research project: A. Conception, B. Organization, C. Execution;
Manuscript preparation: A. Writing of the first draft, B. Review and critique.
N.V.: 1A, 1B, 1C, 2A, 2B
M.L.: 1C, 2B
R.R.: 1C, 2B
A.J.H.: 1C, 2B
T.G.: 1C, 2B
D.A.: 1C, 2B
C.G.: 1C, 2B
Y.B.‐S.: 1C, 2B
H.Z.: 1C, 2B
D.G.G.: 1A, 1B, 1C, 2B
H.R.M.: 1A, 1B, 1C, 2B
T.F.: 1A, 1B, 1C, 2B.
Acknowledgments
Cohort studies: Tracking Parkinson's is primarily funded and supported by Parkinson's UK. It is also supported by the National Institute for Health Research Dementias and Neurodegenerative Diseases Research Network. This research was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and Cambridge BRC. The UCL Movement Disorders Centre is supported by the Edmond J. Safra Philanthropic Foundation.
Biomarker analysis: Work on the biomarkers of progression in Parkinson's and related disorders is supported by Parkinson's UK and the PSP Association.
This research was funded in whole or in part by Aligning Science Across Parkinson's (grant no.: ASAP‐000478) through The Michael J. Fox Foundation for Parkinson's Research. For open access, the author has applied a CC BY public copyright license to all author‐accepted manuscripts resulting from this submission.
Relevant conflicts of interest/financial disclosures: The authors declare that there are no conflicts of interest relevant to this work.
Funding agencies: H.Z. is a Wallenberg scholar supported by grants from the Swedish Research Council (2018‐02532); the European Research Council (681712 and 101053962); the Swedish State Support for Clinical Research (ALFGBG‐71320); the Alzheimer Drug Discovery Foundation, USA (201809‐2016862); the AD Strategic Fund and the Alzheimer's Association (ADSF‐21‐831376‐C, ADSF‐21‐831381‐C, and ADSF‐21‐831377‐C); the Olav Thon Foundation; the Erling‐Persson Family Foundation; Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2019‐0228); the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska–Curie grant agreement number 860197 (MIRIADE); the European Union Joint Programme—Neurodegenerative Disease Research (JPND2021‐00694); and the UK Dementia Research Institute at UCL (UKDRI‐1003). D.G.G. has received grant funding from the Neurosciences Foundation, Michael's Movers, and Parkinson's UK.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
References
- 1. Uyar M, Lezius S, Buhmann C, et al. Diabetes, glycated haemoglobin (HbA1C), and neuroaxonal damage in Parkinson's disease (MARK‐PD study). Mov Disord 2022;37(6):1299–1304. 10.1002/mds.29009 [DOI] [PubMed] [Google Scholar]
- 2. Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 2019;90:870–881. [DOI] [PubMed] [Google Scholar]
- 3. Athauda D, Evans J, Wernick A, et al. The impact of type 2 diabetes in Parkinson's disease. In submission. Mov Disord 2022; in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Vijiaratnam N, Lawton M, Heselgrave A, et al. Combining biomarkers for prognostic modelling of Parkinson's disease. J Neurol Neurosurg Psychiatry Epub ahead of print 2022;0:1–9. 10.1136/jnnp-2021-328365 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Athauda D, Foltynie T. Insulin resistance and Parkinson's disease: a new target for disease modification? Prog Neurobiol 2016;145‐146:98–120. [DOI] [PubMed] [Google Scholar]
- 6. Vicente Miranda H, Szego ÉM, Oliveira LMA, et al. Glycation potentiates α‐synuclein‐associated neurodegeneration in synucleinopathies. Brain 2017;140:1399–1419. [DOI] [PubMed] [Google Scholar]
- 7. Millere E, Rots D, Simren J, et al. Plasma neurofilament light chain as a potential biomarker in Charcot‐Marie‐tooth disease. Eur J Neurol 2021;28(3):974–981. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.